Biogen is a multinational biopharmaceutical company based in Cambridge, Massachusetts, United States. The company specializes in neurology, immunology, and oncology therapies with a focus on developing treatments for serious diseases that do not have adequate treatment options. Biogen is committed to creating innovative therapies that can positively impact patients’ lives and enhance global healthcare.

Biogen was established in 1978 by a group of biologists, including Kenneth Murray and Phillip Allen Sharp, who aimed to create treatments for serious illnesses.

Since then, Biogen has become one of the world’s largest biopharmaceutical companies, with a presence in over 90 countries. The company’s primary focus is on developing treatments for neurological disorders such as multiple sclerosis (MS) and spinal muscular atrophy (SMA).

One of Biogen’s most successful products is TECFIDERA. This drug was approved by the US Food and Drug Administration (FDA) in 2013, as a treatment for relapsing-remitting multiple sclerosis. TECFIDERA is a medication that helps to reduce the frequency of relapses in patients with MS by reducing the inflammation in the central nervous system that causes nerve damage. The drug has been a significant breakthrough in MS treatment, and it has since become the most prescribed oral treatment for MS in the US.

Biogen is also working on SMA treatments. SMA is a genetic disorder that affects the motor neurons in the spinal cord and can lead to muscle weakness and atrophy. In 2016, Biogen received FDA approval for SPINRAZA, a treatment for SMA. SPINRAZA is the first and only treatment for SMA that directly targets the root cause of the disease by increasing the production of the missing or damaged SMN protein in motor neurons. The drug has been a significant advancement in SMA treatment, and it has been shown to significantly improve the quality of life for patients with the disease.

Biogen is also investing in immunology-related research. In 2013, the company launched PLEGRIDY, a medication for the treatment of relapsing-remitting multiple sclerosis. PLEGRIDY is a pegylated form of interferon beta-1a, which means that it has an extended half-life in the body, allowing for less frequent dosing. The drug has been shown to be effective in reducing relapses and slowing down the progression of MS.

The company’s current pipeline includes treatments for Alzheimer’s disease, Parkinson’s disease, and other neurological disorders. Biogen recently announced a partnership with Ionis Pharmaceuticals, a biopharmaceutical company based in California, to develop drugs targeting neurological disorders such as ALS (amyotrophic lateral sclerosis).

Biogen has a strong commitment to sustainability and corporate responsibility. The company has implemented numerous green initiatives to reduce its environmental impact, such as a goal to reduce its greenhouse gas emissions by 80% by 2040. Biogen also invests in philanthropic programs to support research and disease education to improve healthcare access around the world.

In conclusion, Biogen is a leading global biopharmaceutical company that is dedicated to developing innovative treatments for serious illnesses. The company’s focus on neurological disorders has resulted in breakthrough medications such as TECFIDERA and SPINRAZA, which have helped millions of patients worldwide. Biogen’s commitment to sustainability and corporate responsibility is commendable, and the company’s continued investment in research and development demonstrates its dedication to enhancing global healthcare.

Quest'articolo è stato scritto a titolo esclusivamente informativo e di divulgazione. Per esso non è possibile garantire che sia esente da errori o inesattezze, per cui l’amministratore di questo Sito non assume alcuna responsabilità come indicato nelle note legali pubblicate in Termini e Condizioni
Quanto è stato utile questo articolo?
0Vota per primo questo articolo!